Currently, combination therapy of anti-TIGIT and anti-PD-L1 is being researched as a treatment option for cancers such as lung cancer,47 glioblastoma, and neuroblastoma.48,49 In the CITYSCAPE phase II clinical trial, Tiragolumab was combined with anti-PD-L1 treatment in PD-L1 positive non-small cell lung carcinoma patients.47 Dual targeting with Tiragolumab and Atezolizumab showed promising results in liver cancer additive to standard care.28 Our data also strongly suggest to combine anti-TIGIT with anti-PD-L1 therapy to boost NK cell efficiency in MB.50,51. This evidence concerns the gene TIGIT and cancer.